



Silex included in Global X Uranium ETF (NYSE: URA)

2 February 2023

Silex Systems Limited (Silex) (ASX: SLX; OTCQX: SILXY) confirms that it has been included in the Global X Uranium Exchange Traded Fund (ETF) (NYSE: URA) as a non-pure-play uranium stock, effective 1 February 2023 (US time). The Global X Uranium ETF provides investors with access to a range of companies that are involved in the global market for uranium mining and the production of nuclear technology components. The Global X Uranium ETF is the largest uranium ETF in the world, with total assets under management of US\$1.77 billion.

To be eligible to be included in the Global X Uranium ETF, a number of selection criteria are required to be met, including market capitalisation, and daily trading volume thresholds. Selection into the Global X Uranium ETF is based on the analysis of the Solactive Global Uranium and Nuclear Components Total Return Index.

Michael Goldsworthy, Silex's CEO/Managing Director said:

"Inclusion in the Global X Uranium ETF is a very positive development for Silex, GLE and the SILEX technology as we move towards the commercialisation of our unique third generation uranium enrichment technology. The SILEX technology is being commercialised for the uranium enrichment application in conjunction with our US-based exclusive licensee, Global Laser Enrichment LLC, of which Silex owns 51% and our joint venture partner Cameco Corporation owns 49%. GLE, based in Wilmington, NC, is currently assembling a pilot demonstration facility which aims to demonstrate the uranium enrichment technology at commercial scale as early as 2024."

"We are delighted with the recognition of our inclusion into the Global X Uranium ETF and look forward to continuing to build our business case in the uranium production and uranium enrichment sectors of the global nuclear fuel cycle," he added.

Authorised for release by the Silex Board of Directors.

Further information on the Company's activities can be found on the Silex website: www.silex.com.au or by contacting:

Michael Goldsworthy

CEO/Managing Director

T +61 2 9704 8888

E investor.relations@silex.com.au

Julie Russell

CFO/Company Secretary

T +61 2 9704 8888

E investor.relations@silex.com.au

Forward Looking Statements and Risk Factors:

About Silex Systems Limited (ASX: SLX) (OTCQX: SILXY)

Silex Systems Limited ABN 69 003 372 067 (Silex) is a technology commercialisation company whose primary asset is the SILEX laser enrichment technology, originally developed at the Company's technology facility in Sydney, Australia. The SILEX technology has been under development for uranium enrichment jointly with US-based exclusive licensee Global Laser Enrichment LLC (GLE) for a number of years. Success of the SILEX uranium enrichment technology development program and the proposed Paducah commercial project remain subject to a number of factors including the satisfactory completion of the engineering scale-up program and nuclear fuel market conditions and therefore remains subject to associated risks.

Silex is also at various stages of development of additional commercial applications of the SILEX technology, including the production of 'Zero-Spin Silicon' for the emerging technology of silicon-based quantum computing. The 'Zero-Spin Silicon' project remains dependent on the outcomes of the project and the viability of silicon quantum computing and is therefore subject to various risks. The commercial future of the SILEX technology is therefore uncertain and any plans for commercial deployment are speculative.

Additionally, Silex has an interest in a unique semiconductor technology known as 'cREO®' through its 100% ownership of subsidiary Translucent Inc. The cREO® technology developed by Translucent has been acquired by IQE Plc based in the UK. IQE has paused the development of the cREO® technology until a commercial opportunity arises. The future of IQE's development program for cREO® is very uncertain and remains subject to various technology and market risks.

Forward Looking Statements

The commercial potential of these technologies is currently unknown. Accordingly, no guarantees as to the future performance of these technologies can be made. The nature of the statements in this Announcement regarding the future of the SILEX technology as applied to uranium enrichment and Zero-Spin Silicon production, the cREO® technology and any associated commercial prospects are forward-looking and are subject to a number of variables, including but not limited to, unknown risks, contingencies and assumptions which may be beyond the control of Silex, its directors and management. You should not place reliance on any forward-looking statements as actual results could be materially different from those expressed or implied by such forward-looking statements as a result of various risk factors. Further, the forward-looking statements contained in this Announcement involve subjective judgement and analysis and are subject to change due to management's analysis of Silex's business, changes in industry trends, government policies and any new or unforeseen circumstances. The Company's management believes that there are reasonable grounds to make such statements as at the date of this Announcement. Silex does not intend, and is not obligated, to update the forward-looking statements except to the extent required by law or the ASX Listing Rules.

Risk Factors

Risk factors that could affect future results and commercial prospects of Silex include, but are not limited to: ongoing economic and social uncertainty, including in relation to the impacts of the COVID-19 pandemic; geopolitical risks, in particular relating to Russia's invasion of Ukraine and tensions between China and Taiwan which may impact global supply chains among other risks; uncertainties related to the effects of climate change and mitigation efforts; the results of the SILEX uranium enrichment engineering development program; the market demand for natural uranium and enriched uranium; the outcome of the project for the production of 'Zero-Spin Silicon' for the emerging technology of silicon-based quantum computing; the potential development of, or competition from alternative technologies; the potential for third party claims against the Company's ownership of Intellectual Property; the potential impact of prevailing laws or government regulations or policies in the USA, Australia or elsewhere; results from IQE's commercialisation program and the market opportunities for cREO® products; actions taken by the Company's commercialisation partners and other stakeholders that could adversely affect the technology development programs and commercialisation strategies; and the outcomes of various strategies and projects undertaken by the Company.